AbCellera Biologics (ABCL) Shares Outstanding (Diluted Average) (2022 - 2023)
AbCellera Biologics (ABCL) has disclosed Shares Outstanding (Diluted Average) for 3 consecutive years, with $294.3 million as the latest value for Q4 2024.
- For the quarter ending Q4 2024, Shares Outstanding (Diluted Average) rose 1.78% year-over-year to $294.3 million, compared with a TTM value of $294.3 million through Dec 2024, up 1.78%, and an annual FY2024 reading of $294.3 million, up 1.78% over the prior year.
- Shares Outstanding (Diluted Average) was $294.3 million for Q4 2024 at AbCellera Biologics, up from $289.2 million in the prior quarter.
- Across five years, Shares Outstanding (Diluted Average) topped out at $315.8 million in Q3 2022 and bottomed at $284.7 million in Q2 2022.
- Average Shares Outstanding (Diluted Average) over 3 years is $297.2 million, with a median of $289.2 million recorded in 2023.
- The sharpest move saw Shares Outstanding (Diluted Average) dropped 8.57% in 2023, then rose 1.78% in 2024.
- Year by year, Shares Outstanding (Diluted Average) stood at $314.8 million in 2022, then dropped by 8.15% to $289.2 million in 2023, then increased by 1.78% to $294.3 million in 2024.
- Business Quant data shows Shares Outstanding (Diluted Average) for ABCL at $294.3 million in Q4 2024, $289.2 million in Q4 2023, and $288.8 million in Q3 2023.